Rivaroxaban Clinical Trials

7 actively recruiting trials across 2 locations

No change since June 2026

Also known as: B01A F01, Mibrex, Xarelto, Zarixa

Pipeline

Phase 4: 5

Top Sponsors

VA Office of Research and Development1
Shahid Gangalal National Heart Centre1
Seoul National University Hospital1
Ottawa Hospital Research Institute1
Medical University of Gdansk1

Indications

Heart Disease6
Atrial Fibrillation3
Peripartum Cardiomyopathy, Postpartum1
Radial Artery Occlusion1
Left Ventricular Thrombus1

Other5 trials

Anticoagulation in Post MI LV Thrombus Trial in Nepal

Phase 4

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Phase 4

Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization

Phase 4

Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation

N/A

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

N/A

Birmingham, Alabama1 trial

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

University of Alabama Birmingham

Phase 4

Miami, Florida1 trial

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Miami VA Healthcare System, Miami, FL

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.